Blueprint Medicines Corporation

DB:2L9 Stock Report

Market Cap: €5.7b

Blueprint Medicines Management

Management criteria checks 2/4

Blueprint Medicines' CEO is Kate Haviland, appointed in Apr 2022, has a tenure of 2.58 years. total yearly compensation is $6.43M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth €5.37M. The average tenure of the management team and the board of directors is 4.2 years and 9.5 years respectively.

Key information

Kate Haviland

Chief executive officer

US$6.4m

Total compensation

CEO salary percentage12.2%
CEO tenure2.6yrs
CEO ownership0.09%
Management average tenure4.2yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kate Haviland's remuneration changed compared to Blueprint Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$128m

Jun 30 2024n/an/a

-US$205m

Mar 31 2024n/an/a

-US$288m

Dec 31 2023US$6mUS$782k

-US$507m

Sep 30 2023n/an/a

-US$555m

Jun 30 2023n/an/a

-US$554m

Mar 31 2023n/an/a

-US$581m

Dec 31 2022US$6mUS$701k

-US$558m

Sep 30 2022n/an/a

-US$718m

Jun 30 2022n/an/a

-US$702m

Mar 31 2022n/an/a

-US$650m

Dec 31 2021US$4mUS$501k

-US$644m

Sep 30 2021n/an/a

-US$411m

Jun 30 2021n/an/a

US$340m

Mar 31 2021n/an/a

US$325m

Dec 31 2020US$2mUS$461k

US$314m

Sep 30 2020n/an/a

US$333m

Jun 30 2020n/an/a

-US$395m

Mar 31 2020n/an/a

-US$371m

Dec 31 2019US$3mUS$432k

-US$348m

Sep 30 2019n/an/a

-US$362m

Jun 30 2019n/an/a

-US$340m

Mar 31 2019n/an/a

-US$267m

Dec 31 2018US$3mUS$393k

-US$237m

Sep 30 2018n/an/a

-US$205m

Jun 30 2018n/an/a

-US$170m

Mar 31 2018n/an/a

-US$177m

Dec 31 2017US$1mUS$353k

-US$148m

Compensation vs Market: Kate's total compensation ($USD6.43M) is above average for companies of similar size in the German market ($USD3.48M).

Compensation vs Earnings: Kate's compensation has increased whilst the company is unprofitable.


CEO

Kate Haviland (48 yo)

2.6yrs

Tenure

US$6,432,012

Compensation

Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...


Leadership Team

NamePositionTenureCompensationOwnership
Kathryn Haviland
President2.6yrsUS$6.43m0.094%
€ 5.4m
Alexis Borisy
Co-Founder & Directorno dataUS$397.33k0.11%
€ 6.4m
Michael Landsittel
Chief Financial Officer8.8yrsUS$2.19m0.056%
€ 3.2m
Christina Rossi
Chief Operating Officer2.6yrsUS$2.81m0.043%
€ 2.4m
Percy Carter
Chief Scientific Officer3.5yrsUS$2.30m0.078%
€ 4.4m
Fouad Namouni
President of Research & Development4.2yrsUS$2.80m0.050%
€ 2.9m
Ariel Hurley
Senior VP1.8yrsno data0.023%
€ 1.3m
Jenna Cohen
Senior Director & Head of Investor Relationsno datano datano data
Tracey McCain
Executive VP8.2yrsUS$2.34m0.046%
€ 2.6m
Debra Durso-Bumpus
Chief People Officer4.8yrsno data0.019%
€ 1.1m
Julian Baker
Senior Vice President of Corporate Affairsno datano datano data
Becker Hewes
Chief Medical Officer4.5yrsno data0.046%
€ 2.6m

4.2yrs

Average Tenure

54yo

Average Age

Experienced Management: 2L9's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kathryn Haviland
President2.6yrsUS$6.43m0.094%
€ 5.4m
Alexis Borisy
Co-Founder & Director13.6yrsUS$397.33k0.11%
€ 6.4m
George Demetri
Chair of Scientific Advisory Board12.5yrsUS$333.38kno data
Lynn Seely
Lead Independent Director8.6yrsUS$452.33k0.017%
€ 986.4k
Charles Sawyers
Member of Scientific Advisory Boardno datano datano data
Brian Druker
Member of Scientific Advisory Boardno datano datano data
Nicholas Lydon
Member of Scientific Advisory Board & Independent Director13.6yrsUS$417.33k0.088%
€ 5.0m
Lonnel Coats
Independent Director8.8yrsUS$419.33k0%
€ 0
William Hahn
Member of Scientific Advisory Boardno datano datano data
Scott Lowe
Member of Scientific Advisory Boardno datano datano data
Daniella Beckman
Independent Director2.9yrsUS$422.33k0.014%
€ 770.7k
Jeffrey Albers
Chairman10.3yrsUS$526.08k0.24%
€ 13.9m

9.5yrs

Average Tenure

62yo

Average Age

Experienced Board: 2L9's board of directors are considered experienced (9.5 years average tenure).